Sandbox Reserved 1470

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 8: Line 8:
''Porphyromonas gingivalis'' is a Gram-Negative oral anaerobe that leads to periodontitis. It invades periodontal tissues, and evades the host defense mechanisms by a series of virulence factors, such as KGP, that deregulate innate immune and inflammatory responses. This bacteria and its products can enter circulation and contribute to the development of diabetes, cardiovascular disease, and rheumatoid arthritis.
''Porphyromonas gingivalis'' is a Gram-Negative oral anaerobe that leads to periodontitis. It invades periodontal tissues, and evades the host defense mechanisms by a series of virulence factors, such as KGP, that deregulate innate immune and inflammatory responses. This bacteria and its products can enter circulation and contribute to the development of diabetes, cardiovascular disease, and rheumatoid arthritis.
== Relevance ==
== Relevance ==
-
Bacteria are typically beneficial to maintaining a healthy mouth, however, if they are a susceptible host they can become pathogenic <ref>PMID: 23985870</ref>. Once they become pathogenic they can invade tissues and lead to infection and disease. Resistant strains are currently responsible for half of all infections, and resistant pathogens infect over 2 million people annually in the United States. The only way to keep up with these resistant pathogens is by developing new antimicrobials, but the pharmaceutical industry is failing to keep up. By studying KGP, scientists hope to find a suitable inhibitor to eliminate KGP activity, and thus prevent periodontal disease in humans.
+
Bacteria are typically beneficial to maintaining a healthy mouth, however, if they are a susceptible host they can become pathogenic <ref>PMID: 23985870</ref>. Once they become pathogenic they can invade tissues and lead to infection and disease. Resistant strains are currently responsible for half of all infections, and resistant pathogens infect over 2 million people annually in the United States<ref>PMID:24784427</ref>. The only way to keep up with these resistant pathogens is by developing new antimicrobials, but the pharmaceutical industry is failing to keep up. By studying KGP, scientists hope to find a suitable inhibitor to eliminate KGP activity, and thus prevent periodontal disease in humans.
== Structural highlights ==
== Structural highlights ==

Revision as of 21:35, 20 November 2018

This Sandbox is Reserved from October 22, 2018 through April 30, 2019 for use in the course Biochemistry taught by Bonnie Hall at the Grand View University, Des Moines, IA USA. This reservation includes Sandbox Reserved 1456 through Sandbox Reserved 1470.
To get started:
  • Click the edit this page tab at the top. Save the page after each step, then edit it again.
  • Click the 3D button (when editing, above the wikitext box) to insert Jmol.
  • show the Scene authoring tools, create a molecular scene, and save it. Copy the green link into the page.
  • Add a description of your scene. Use the buttons above the wikitext box for bold, italics, links, headlines, etc.

More help: Help:Editing

Structure and Mechanism of Cysteine Peptidase Gingipain K (KGP), a Major Virulence Factor of Porphyromonas gingivitis in Periodontitis

Structure of Cystein Peptidase Gingapain (KGP)

Drag the structure with the mouse to rotate

References

  1. de Diego I, Veillard F, Sztukowska M, Guevara T, Potempa B, Pomowski A, Huntington JA, Potempa J, Gomis-Ruth FX. Structure and mechanism of cysteine peptidase Kgp, a major virulence factor of Porphyromonas gingivalis in periodontitis. J Biol Chem. 2014 Sep 29. pii: jbc.M114.602052. PMID:25266723 doi:http://dx.doi.org/10.1074/jbc.M114.602052
  2. Yongqing T, Potempa J, Pike RN, Wijeyewickrema LC. The lysine-specific gingipain of Porphyromonas gingivalis : importance to pathogenicity and potential strategies for inhibition. Adv Exp Med Biol. 2011;712:15-29. doi: 10.1007/978-1-4419-8414-2_2. PMID:21660656 doi:http://dx.doi.org/10.1007/978-1-4419-8414-2_2
  3. Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, Almeida M, Arumugam M, Batto JM, Kennedy S, Leonard P, Li J, Burgdorf K, Grarup N, Jorgensen T, Brandslund I, Nielsen HB, Juncker AS, Bertalan M, Levenez F, Pons N, Rasmussen S, Sunagawa S, Tap J, Tims S, Zoetendal EG, Brunak S, Clement K, Dore J, Kleerebezem M, Kristiansen K, Renault P, Sicheritz-Ponten T, de Vos WM, Zucker JD, Raes J, Hansen T, Bork P, Wang J, Ehrlich SD, Pedersen O. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013 Aug 29;500(7464):541-6. doi: 10.1038/nature12506. PMID:23985870 doi:http://dx.doi.org/10.1038/nature12506
  4. May M. Drug development: Time for teamwork. Nature. 2014 May 1;509(7498):S4-5. doi: 10.1038/509S4a. PMID:24784427 doi:http://dx.doi.org/10.1038/509S4a
Personal tools